
MedPage Today) — In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention (PCI).
4D-ACS trial investigators…
Read More